Developed by Brazilian scientists, HSP-CAR30 therapy targets the CD30 protein and has successfully completed its initial trial.
- CD30 protein is found on some T cells and B cells (two types of white blood cells). It helps in cancer diagnosis and treatment planning.
- T-cells are special cells whose primary function is cytotoxic, meaning killing other cells.
Key Developments
- Higher Efficacy: It has 100% overall response rate and 50% of patients achieved complete remission.
- Safety and immunity: It has no dose-limiting toxicities, and CAR30+ cells remained detectable in 60% of evaluable patients even a year after infusion.
What is Chimeric Antigen Receptor T-cell (CAR-T) Therapy?
- Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of treatment where a patient's T cells (a kind of white blood cell) are collected from the blood and genetically modified in a laboratory.
- A special receptor called CAR (Chimeric Antigen Receptor) is added to these T cells, enabling them to recognize and attack cancer cells more effectively.
- CAR-T therapy has already shown significant success in treating blood cancers, including Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, and Multiple Myeloma.
